Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.52 |
| ▸ | MBTPS1 | Q14703 | 5/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.47 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.47 |
| ▸ | RPS17 | P08708 | 1/20 | 0.47 |
| ▸ | RPSA | P08865 | 1/20 | 0.47 |
| ▸ | RPS2 | P15880 | 1/20 | 0.47 |
| ▸ | RPL35A | P18077 | 1/20 | 0.47 |
| ▸ | RPL7 | P18124 | 1/20 | 0.47 |
| ▸ | RPL17 | P18621 | 1/20 | 0.47 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.47 |
| ▸ | RPS3 | P23396 | 1/20 | 0.47 |
| ▸ | RPS12 | P25398 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394396 | 0.93 | TACR1 (0.50) | TACR1MBTPS1F10PLAUSLC6A2 | |
| SCHEMBL340465 | 0.90 | SLC6A2 (0.51) | TACR1MBTPS1F10PLAUSLC6A2 | |
| SCHEMBL4912849 | 0.83 | ALOX5 (0.52) | TACR1MBTPS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4210498 | 0.82 | MBTPS1 (0.59) | MBTPS1F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL339372 | 0.78 | TACR1 (0.57) | TACR1MBTPS1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL339220 | 0.75 | TACR1 (0.61) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL341939 | 0.74 | ALOX5 (0.60) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL341134 | 0.74 | SLC6A2 (0.53) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL339704 | 0.73 | TACR1 (0.55) | TACR1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL340969 | 0.73 | ALOX5 (0.55) | MBTPS1SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| US-9296694-B2 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARMACEUTICALS INC. | 2015-09-17 | — | — | US | disclosed |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2011-12-08 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060194834-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | disclosed |
| US-6756393-B2 | AMIDES AND UREAS N-SUBSTITUTED WITH PIPERIDINE OR NORTROPANE; SEROTONIN INVERSE AGONISTS OR ANTAGONISTS; ANTIPSYCHOTIC | ACADIA PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259291-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | TACR1 124/4885MBTPS1 1883/4885F10 4788/4885 |
| US-20110301191-A1 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | TACR1 147/4885MBTPS1 2026/4885F10 4099/4885 |
| US-20060194834-A1 | Azacyclic compounds | HTR6, HTR5A, HNMT | TACR1 116/4885MBTPS1 1389/4885F10 4693/4885 |
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | TACR1 124/4885MBTPS1 1883/4885F10 4788/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | TACR1 124/4885MBTPS1 1883/4885F10 4788/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | TACR1 137/4885MBTPS1 444/4885F10 4543/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | TACR1 147/4885MBTPS1 2026/4885F10 4099/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | TACR1 124/4885MBTPS1 1883/4885F10 4788/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | TACR1 66/4885MBTPS1 1286/4885F10 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.